Quick Answer
CNBX Pharmaceuticals Inc. reported Operating Income of -$271.7 thousand for fiscal year 2025.
CNBX Pharmaceuticals Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$271.7K | +53.4% |
| 2024 | -$583.1K | +37.4% |
| 2023 | -$931.4K | +68.5% |
| 2022 | -$2.95M | -13.6% |
| 2021 | -$2.60M | +14.6% |
| 2020 | -$3.04M | +7.9% |
| 2019 | -$3.30M | +13.3% |
| 2018 | -$3.81M | -105.4% |
| 2017 | -$1.85M | -560.5% |
| 2016 | -$280.7K | +47.7% |
| 2015 | -$536.5K | -148.2% |
| 2014 | -$216.1K | -271.9% |
| 2013 | -$58.1K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | -$64.0K | -73.7% | -58.5% |
| May 31, 2025 | -$40.4K | +73.5% | +37.6% |
| February 28, 2025 | -$64.7K | +68.6% | -75.8% |
| November 30, 2024 | -$36.8K | +78.6% | +75.8% |
| May 31, 2024 | -$152.3K | +12.0% | +26.2% |
| February 29, 2024 | -$206.4K | +17.4% | -20.1% |
| November 30, 2023 | -$171.9K | +50.4% | +0.7% |
| May 31, 2023 | -$173.1K | +72.7% | +30.8% |
- CNBX Pharmaceuticals Inc. showed an increase of +53.4% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, CNBX Pharmaceuticals Inc.’s operating income has declined by 367.5% (from -$58.1 thousand to -$271.7 thousand).
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: